PCAB Treatment: A New Weapon to Combat Erosive Esophagitis PCAB Treatment: A New Weapon to Combat Erosive Esophagitis
Potassium-competitive acid blockers (PCABs) provide an effective new approach to combat erosive esophagitis, particularly in PPI therapy-refractory patients, reports Dr John Pandolfino.Medscape (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 19, 2024 Category: Gastroenterology Tags: Gastroenterology Commentary Source Type: news
Q & A: Erosive Esophagitis Treatment Q & A: Erosive Esophagitis Treatment
Cristian Puerta, MD, reviews treatment guidelines in erosive esophagitis and the role of potassium-competitive acid blockers (PCABs) in the management of patients with severe disease.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 3, 2024 Category: Gastroenterology Tags: Gastroenterology Commentary Source Type: news
Erosive Esophagitis: 5 Things to Know Erosive Esophagitis: 5 Things to Know
Erosive esophagitis can cause serious complications, including cancer. These five things to know are key to identifying risk factors, preventive strategies, and latest treatments.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 2, 2024 Category: Gastroenterology Tags: Gastroenterology Commentary Source Type: news
FDA Approves Voquezna for Erosive Esophagitis, GERD
TUESDAY, Nov. 7, 2023 -- The U.S. Food and Drug Administration has approved Voquezna (vonoprazan), a novel potassium-competitive acid blocker, as a new treatment for adults for with all grades of erosive esophagitis or erosive gastroesophageal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2023 Category: Pharmaceuticals Source Type: news
FDA OKs New Treatment for Erosive Esophagitis FDA OKs New Treatment for Erosive Esophagitis
Vonoprazan (Voquezna) is indicated for the healing and maintenance of healing of all grades of erosive esophagitis, as well as relief of associated heartburn in adults.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 2, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news
New Option Approved for Erosive Esophagitis
(MedPage Today) -- The FDA approved vonoprazan (Voquezna) for all grades of erosive gastroesophageal reflux disease (GERD) and heartburn relief associated with the condition, Phathom Pharmaceuticals announced on Wednesday.
Vonoprazan, a first... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 2, 2023 Category: Gastroenterology Source Type: news
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 3, 2023 Category: Drugs & Pharmacology Source Type: news
Vonoprazan Promising for Erosive Esophagitis Vonoprazan Promising for Erosive Esophagitis
The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 18, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Vonoprazan Just as Good or Better Than Lansoprazole for Erosive Esophagitis
(MedPage Today) -- Vonoprazan (Voquezna) was noninferior to lansoprazole (Prevacid) for healing patients with erosive esophagitis, and was superior for maintaining healing, a randomized trial showed.
In a modified intention-to-treat analysis including... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 12, 2022 Category: Gastroenterology Source Type: news
Efficacy and Safety of Keverprazan for Erosive Esophagitis Efficacy and Safety of Keverprazan for Erosive Esophagitis
In this study, keverprazan, a novel potassium-competitive acid blocker, showed comparable safety and efficacy to lansoprazole in treating erosive esophagitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 14, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 25, 2022 Category: Drugs & Pharmacology Source Type: news
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 14, 2022 Category: Drugs & Pharmacology Source Type: news
H. Pylori Infection, GERD, and Its Complications H. Pylori Infection, GERD, and Its Complications
This review aimed to elucidate the association between H. pylori infection and GERD symptoms, erosive esophagitis, and Barrett ' s esophagus. Might H. pylori infection provide a protective effect?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 3, 2021 Category: Consumer Health News Tags: None Journal Article Source Type: news
Jubilant Cadista Inc recalls 63,216 bottles of erosive esophagitis tablets
The reason for the recall is "CGMP Deviation: Presence of dark brown discoloration on edges of tablets," USFDA said. The ongoing voluntary recall is a class II recall, the report said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 27, 2019 Category: Pharmaceuticals Source Type: news
Relief of Heartburn in Patients With Erosive Esophagitis Relief of Heartburn in Patients With Erosive Esophagitis
Does a new potassium-competitive acid blocker, vonoprazan, provide more rapid relief of heartburn than standard treatment with a proton-pump inhibitor?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
